These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24593920)

  • 1. Probabilistic uncertainty analysis of epidemiological modeling to guide public health intervention policy.
    Gilbert JA; Meyers LA; Galvani AP; Townsend JP
    Epidemics; 2014 Mar; 6():37-45. PubMed ID: 24593920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P; Boiron L; Araujo RR; Lopez JG; Petitjean A; de Albuquerque Luna EJ
    BMC Public Health; 2020 Sep; 20(1):1374. PubMed ID: 32907562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland.
    Nagy L; Heikkinen T; Sackeyfio A; Pitman R
    Pharmacoeconomics; 2016 Sep; 34(9):939-51. PubMed ID: 27423657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising age coverage of seasonal influenza vaccination in England: A mathematical and health economic evaluation.
    Hill EM; Petrou S; Forster H; de Lusignan S; Yonova I; Keeling MJ
    PLoS Comput Biol; 2020 Oct; 16(10):e1008278. PubMed ID: 33021983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive.
    Mogasale V; Barendregt J
    Aust N Z J Public Health; 2011 Apr; 35(2):180-6. PubMed ID: 21463417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
    Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Zimmerman RK
    J Am Geriatr Soc; 2016 Oct; 64(10):2126-2131. PubMed ID: 27709600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany.
    Scholz SM; Weidemann F; Damm O; Ultsch B; Greiner W; Wichmann O
    Value Health; 2021 Jan; 24(1):32-40. PubMed ID: 33431151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the optimal target age group for seasonal influenza vaccination in Japan.
    Tsuzuki S; Baguelin M; Pebody R; van Leeuwen E
    Vaccine; 2020 Jan; 38(4):752-762. PubMed ID: 31735503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A marginal benefit approach for vaccinating influenza "superspreaders".
    Skene KJ; Paltiel AD; Shim E; Galvani AP
    Med Decis Making; 2014 May; 34(4):536-49. PubMed ID: 24740238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty.
    Ndeffo Mbah ML; Medlock J; Meyers LA; Galvani AP; Townsend JP
    Vaccine; 2013 Jun; 31(30):3079-89. PubMed ID: 23684837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding optimal vaccination strategies under parameter uncertainty using stochastic programming.
    Tanner MW; Sattenspiel L; Ntaimo L
    Math Biosci; 2008 Oct; 215(2):144-51. PubMed ID: 18700149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic.
    Bartsch SM; Taitel MS; DePasse JV; Cox SN; Smith-Ray RL; Wedlock P; Singh TG; Carr S; Siegmund SS; Lee BY
    Vaccine; 2018 Nov; 36(46):7054-7063. PubMed ID: 30340884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active learning to understand infectious disease models and improve policy making.
    Willem L; Stijven S; Vladislavleva E; Broeckhove J; Beutels P; Hens N
    PLoS Comput Biol; 2014 Apr; 10(4):e1003563. PubMed ID: 24743387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinate before the next pandemic?
    Stöhr K
    Nature; 2010 May; 465(7295):161. PubMed ID: 20463719
    [No Abstract]   [Full Text] [Related]  

  • 18. Influenza cost and cost-effectiveness studies globally--a review.
    Peasah SK; Azziz-Baumgartner E; Breese J; Meltzer MI; Widdowson MA
    Vaccine; 2013 Nov; 31(46):5339-48. PubMed ID: 24055351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model.
    Pitman RJ; Nagy LD; Sculpher MJ
    Vaccine; 2013 Jan; 31(6):927-42. PubMed ID: 23246550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future epidemiological and economic impacts of universal influenza vaccines.
    Sah P; Alfaro-Murillo JA; Fitzpatrick MC; Neuzil KM; Meyers LA; Singer BH; Galvani AP
    Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20786-20792. PubMed ID: 31548402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.